Perrigo’s Next CEO Has Long OTC Brands History
Lockwood-Taylor Moves From Bayer As Perrigo Awaits Decision On OTC Oral Contraceptive
Executive Summary
Patrick Lockwood-Taylor starts as president/CEO on 30 June, succeeding Murray Kessler as Perrigo awaits FDA decision on subsidiary HRA’s proposal for first US OTC sales of daily oral contraceptive. He’s moving from president of Bayer AG’s US business and regional president, consumer health North America.
You may also be interested in...
US Health And Wellness Executive Decisions: Perrigo, Nestle, Flexpower Health, Herbalife, More
NBA star Antetokounmpo invests in Flexpower; Perrigo changes Americas helm; Bündchen models healthy lifestyle for Gaia; Vit-Best appoints growth chief; Olympian Jennings works with Protein Puck; and more.
OTC Brands In Hand, Perrigo Prepares To Pump More Revenue From Private Label Portfolio
“I think that is a value creating opportunity for us as well. We have incredible consumer reach in the US,” says CEO Patrick Lockwood-Taylor. Few companies can say, in “certain categories 80% of the units sold come from us.”
Perrigo Prepares To Pioneer US OTC Birth Control Sales As ‘Supply Chain Reinvention’ Continues
Firm reports Q2 net sales up 6.4% to $1.2bn while organic measure was 0.8% growth after a 2.7 percentage point drag from SKU prioritization moves. Investment planned over second half to prepare for launch of Opill sales.